Other Events ·
Alto Neuroscience, Inc. announced that its estimated cash, cash equivalents, and restricted cash totaled approximately…
ANROAlto Neuroscience, Inc.
Alto Neuroscience, Inc. announced that its estimated cash, cash equivalents, and restricted cash totaled approximately $244.2 million as of June 30, 2026. The company also announced plans to accelerate and expand the clinical development of its ALTO-207 program, which includes conducting an additional Phase 3 trial for treating treatment-resistant depression. Alto Neuroscience, Inc. is a biotechnology company focused on neurological disorders.